QSI Q2 2025: Installed Base Grows to 65% International, Driving Shift to Consumable Revenue Amid NIH Headwinds
QSI’s Q2 revealed the full brunt of NIH funding uncertainty, nearly halting US academic capital sales and forcing a pivot to alternative acquisition models. The company’s strategic focus is now on expanding its installed base, especially overseas and in pharma/biotech, to drive recurring consumable revenue. Management’s tight cost control and long cash runway contrast with top-line softness, as QSI bets on innovation and installed base growth to outlast current funding disruptions.
Summary
- Installed Base Expansion: QSI is leveraging flexible acquisition models to grow its global footprint, especially outside the US.
- Recurring Consumable Focus: The shift from capital sales to consumable pull-through is now central to revenue strategy.
- Innovation Pipeline Builds Optionality: Multiple new kits and the Proteus platform set up long-term growth, despite near-term capital market constraints.
Business Overview
QSI develops and commercializes next-generation protein sequencing instruments and consumable kits, enabling researchers to analyze proteomes at single-molecule resolution. Revenue is generated through sales of its Platinum Pro instruments and recurring sales of consumable kits, with customers spanning academic labs, pharma/biotech, government, and industrial research. The business is increasingly emphasizing consumable pull-through, as recurring consumable sales offer higher margins and stickier revenue compared to one-time instrument sales.
Performance Analysis
Q2 results demonstrated acute sensitivity to US academic market capital constraints, as NIH funding uncertainty led to a near halt in domestic instrument sales. Revenue fell below expectations, with capital sales as the main drag, while consumable purchases slightly exceeded internal forecasts.
International markets now represent 65% of QSI’s installed base, providing some insulation from US-specific funding headwinds. The company doubled its pharma/biotech opportunity funnel to over 60 accounts, though management cautions these have longer sales cycles and not all will convert. Gross margin benefited from low-cost inventory, but management expects continued variability as sales mix and inventory accounting adjustments fluctuate.
- Consumable Revenue Resilience: Despite capital sales softness, consumable purchases remained steady across all customer segments, especially pharma/biotech and government.
- Cost Discipline: Adjusted operating expenses were flat year-over-year, reflecting tight controls even as R&D and product development continue.
- Cash Runway Extended: With $214 million in cash and a $50 million capital raise, QSI expects to fund operations into Q2 2028, providing strategic flexibility.
While the capital sales environment remains challenged, QSI’s ability to maintain cost discipline and pivot toward recurring consumable revenue is a critical offset, setting up for a potential rebound as market conditions normalize.
Executive Commentary
"We view growing our installed base, not just as a revenue driver, but as a strategic mode. With every new lab that implements Platinum Pro, we expect to see increasing consumable sales, scientific validation, and customer advocacy. The cumulative impact of this cycle is key to long-term value creation."
Jeff Hawkins, President & Chief Executive Officer
"Keeping our overall spend flat would not have been possible without continued cost control measures and allocating our capital to fund and accelerate the highest return projects for our shareholders."
Jeff Kye, Chief Financial Officer
Strategic Positioning
1. Installed Base as Strategic Moat
QSI is prioritizing installed base expansion, using flexible acquisition options—capital sales, reagent rentals, third-party leasing, and selective placements—to overcome capital budget freezes. The company’s international focus (65% of base) and emphasis on pharma/biotech are designed to diversify exposure away from the volatile US academic market.
2. Recurring Consumable Revenue Model
With capital sales unpredictable, QSI is leaning into the higher-margin, recurring revenue from consumables, especially as pharma/biotech customers tend to purchase at a steady clip. The company’s new acquisition models are specifically structured to maximize consumable pull-through, even if instrument revenue lags.
3. Innovation Roadmap and Product Pipeline
QSI’s R&D pipeline remains robust, with the V4 sequencing kit and V3 library prep kit on track for launch, both aimed at expanding addressable applications and improving system performance. The Proteus platform, a next-generation system targeting multi-year growth, remains on schedule for a 2026 launch, with key development milestones achieved ahead of plan.
4. AI-Driven Recognizer Development
Leveraging proprietary binding data and advanced AI design tools, QSI is accelerating the development of amino acid recognizers, aiming for full proteome coverage and shortening R&D timelines. This approach is expected to yield faster innovation cycles and reinforce competitive differentiation.
5. Financial Flexibility and Cost Structure
Cost controls and a conservative capital allocation approach have enabled QSI to keep adjusted operating expenses flat while funding new product development. The recent $50 million capital raise further extends the cash runway, allowing QSI to weather short-term market disruptions and invest in high-return initiatives.
Key Considerations
This quarter’s results underscore the importance of business model flexibility and operational discipline in navigating external funding shocks. QSI’s ability to adapt its go-to-market strategy and protect its innovation pipeline will be pivotal in determining long-term competitiveness.
Key Considerations:
- Alternative Acquisition Models Gain Traction: Early adoption of reagent rental and leasing models is helping QSI place instruments without upfront capital, but the pace of revenue recovery will depend on consumable pull-through and conversion rates.
- Pharma/Biotech Funnel Expansion: Doubling of pharma/biotech opportunities demonstrates traction, yet conversion to sales is gated by long sales cycles and market adoption rates.
- International Diversification: With 65% of the installed base outside the US, QSI is less exposed to US-specific capital headwinds, but must continue building global channel strength.
- R&D Productivity Remains High: Despite flat spending, QSI continues to deliver on ambitious product milestones, positioning itself for future growth as market conditions improve.
Risks
Persistent NIH funding uncertainty and capital market constraints could prolong softness in instrument sales, delaying the inflection to higher recurring consumable revenue. Execution risk remains high as QSI balances innovation investment with cost discipline, and there is ongoing exposure to global economic volatility and potential tariff changes. Management’s ability to convert expanded opportunity funnels into actual revenue will be a key determinant of long-term success.
Forward Outlook
For Q3 2025, QSI did not provide formal revenue guidance, citing continued uncertainty around NIH funding and capital sales. However, management expects:
- Continued softness in capital instrument revenue, with gradual improvement possible by Q4 as installed base and consumable pull-through increase.
- Adjusted operating expense guidance for full year 2025 lowered to $98 million or less, with total cash use capped at $95 million, including litigation-related payments.
Management highlighted several factors that will shape the outlook:
- Momentum from new acquisition models and consumable revenue growth is expected to offset some capital sales headwinds over time.
- R&D milestones, including the V4 sequencing kit launch and progress on Proteus, remain on track and are expected to drive future demand.
Takeaways
QSI’s Q2 2025 call reveals a company in strategic transition, using flexibility and discipline to navigate a tough funding environment while investing in long-term growth levers.
- Installed Base and Consumable Focus: The pivot to recurring consumable revenue and global installed base expansion is now central to QSI’s business model, reducing reliance on lumpy capital sales.
- Cost and Cash Discipline: Flat operating expenses and a cash runway into 2028 provide a margin of safety for continued investment in innovation and market development.
- Future Watchpoints: Investors should monitor the pace of installed base growth, consumable pull-through, and conversion of pharma/biotech opportunities, as well as updates on the Proteus platform and new kit launches.
Conclusion
QSI is navigating a complex funding environment by doubling down on its installed base, recurring consumable revenue, and product innovation. The company’s operational discipline and financial flexibility position it to capitalize on market recovery, but execution on funnel conversion and product launches will be decisive for long-term value creation.
Industry Read-Through
QSI’s quarter offers a cautionary signal for all capital equipment providers exposed to US academic and government funding cycles. The rapid pivot to alternative acquisition models and emphasis on recurring consumable revenue reflect a broader industry trend toward subscription-like business models in life sciences instrumentation. Companies with global reach and a robust innovation pipeline are better positioned to weather funding shocks, while those reliant on US academic capital budgets face prolonged uncertainty. The focus on AI-driven product development and modular kit launches also highlights the increasing importance of speed and flexibility in R&D as a competitive differentiator across the sector.